Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carboprost Tromethamine Market
Carboprost Tromethamine Market Size
- Report ID: GMI8526
- Published Date: Mar 2024
- Report Format: PDF
Carboprost Tromethamine Market Size
Carboprost Tromethamine Market size was valued at USD 1.5 billion in 2023 and is estimated to grow at a CAGR of 7.9% between 2024 and 2032. Carboprost tromethamine is a synthetic prostaglandin analogue medication, along with other abortion drugs, which estimated to reach USD 49.3 billion by 2032, are used in obstetrics and gynecology for various purposes including the induction of abortion, termination of pregnancy, treatment of postpartum, and management of uterine atony.
The increasing prevalence of postpartum hemorrhage has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO) in 2023, approximately 14 million women experienced postpartum hemorrhage, leading to approximately 70,000 maternal deaths globally. Therefore, integrating postpartum health supplements into comprehensive care strategies can further enhance maternal recovery and mitigate the risks associated with postpartum hemorrhage, addressing a critical healthcare challenge.
Furthermore, increasing initiatives by government and various organizations, rising publicly funded family planning services, among other contributing factors are estimated to propel the growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Carboprost Tromethamine Market Size in 2023: | USD 1.5 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 7.9% |
| 2024 – 2032 Value Projection: | USD 3 Billion |
| Historical Data for: | 2018 – 2023 |
| No. of Pages: | 130 |
| Tables, Charts & Figures: | 150 |
| Segments covered: | Application, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Carboprost Tromethamine Market Scope
